BioSpace News Archive

Seres Therapeutics, Inc today announced that enrollment in Cohort 2 in its SER-155 Phase 1b study is underway.

ImmPACT Bio USA , Inc. today announced the appointment of Biren Amin, M.B.A., to its board of directors.

Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.

Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine (NEJM).

Medexus Pharmaceuticals announced its operating and financial results and provided a business update for the company’s third fiscal quarter ended December 31, 2022.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent for injection into the lumbar disc.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022.

GC Biopharma, a leading provider of biopharmaceutical products in South Korea, announced that the World Health Organization has awarded prequalification to filling and finish plant on February 3 2023, located in Ochang, South Korea.

MediciNova, Inc. today announced that Health Canada has completed its review of the clinical trial application and has granted authorization to commence a grant-funded, multi-center, randomized, clinical trial to evaluate MN-166 (ibudilast) and other therapies for the treatment of Long COVID, the lingering symptoms of COVID-19.

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, prior to its earnings call at 8:00 a.m. ET.